Serum Copeptin Levels Predict Clinical Outcomes After Successful Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Serum copeptin has been demonstrated to be useful in early risk stratification and prognostication of patients with acute myocardial infarction (AMI). However, the prognostic value of copeptin after percutaneous coronary intervention (PCI) for clinical outcomes remains uncertain. We investigated the prognostic role of serum copeptin levels immediately after successful PCI as a prognostic marker for major adverse cardiac events (MACE; comprising death, repeat PCI, recurrent MI, or coronary artery bypass grafting) in patients with AMI. Methods: A retrospective study was performed in 149 patients with AMI who successfully received PCI. Serum copeptin levels were analyzed in blood samples collected immediately after PCI. The association between copeptin levels and MACE during the follow-up period was evaluated. Results: MACE occurred in 34 (22.8%) patients during a median follow-up of 30.1 months. MACE patients had higher copeptin levels than non-MACE patients did. Multiple logistic regression analysis showed that the increase in serum copeptin levels was associated with increased MACE incidence (odds ratio=1.6, P=0.005). Conclusions: A high level of serum copeptin measured immediately after PCI was associated with MACE in patients with AMI during long-term follow-up. Serum copeptin levels can serve as a prognostic marker in patients with AMI after successful PCI.
Abstract
Background: Serum copeptin has been demonstrated to be useful in early risk stratification and prognostication of patients with acute myocardial infarction (AMI). However, the prognostic value of copeptin after percutaneous coronary intervention (PCI) for clinical outcomes remains uncertain. We investigated the prognostic role of serum copeptin levels immediately after successful PCI as a prognostic marker for major adverse cardiac events (MACE; comprising death, repeat PCI, recurrent MI, or coronary artery bypass grafting) in patients with AMI. Methods: A retrospective study was performed in 149 patients with AMI who successfully received PCI. Serum copeptin levels were analyzed in blood samples collected immediately after PCI. The association between copeptin levels and MACE during the follow-up period was evaluated. Results: MACE occurred in 34 (22.8%) patients during a median follow-up of 30.1 months. MACE patients had higher copeptin levels than non-MACE patients did. Multiple logistic regression analysis showed that the increase in serum copeptin levels was associated with increased MACE incidence (odds ratio=1.6, P=0.005). Conclusions: A high level of serum copeptin measured immediately after PCI was associated with MACE in patients with AMI during long-term follow-up. Serum copeptin levels can serve as a prognostic marker in patients with AMI after successful PCI.
참고문헌 (29)
- Stone GW, "A prospective natural-history study of coronary atherosclerosis", N Engl J Med, 364, pp.226~235 (2011)
- Zellweger MJ, "Coronary artery disease progression late after successful stent implantation", J Am Coll Cardiol, 59, pp.793~799 (2012)
- Akkerhuis KM, "Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?", Circulation, 105, pp.554~556 (2002)
- Ioannidis JP, "Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention", J Am Coll Cardiol, 42, pp.1406~1411 (2003)
- Jang JS, "Prognostic value of creatine kinase-myocardial band isoenzyme elevation following percutaneous coronary intervention: a meta-analysis", Catheter Cardiovasc Interv, 81, pp.959~967 (2013)
- Bolignano D, "Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology", Clin Chem Lab Med, 52, pp.1447~1456 (2014)
- Morgenthaler NG, "Copeptin: clinical use of a new biomarker", Trends Endocrinol Metab, 19, pp.43~49 (2008)
- Land H, "Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor", Nature, 295, pp.299~303 (1982)
- Morgenthaler NG, "Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin", Clin Chem, 52, pp.112~119 (2006)
- Tasevska I, "Copeptin predicts coronary artery disease cardiovascular and total mortality", Heart, 102, pp.127~132 (2016)
- Tu WJ, "Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke", J Neuroendocrinol, 25, pp.771~778 (2013)
- Voors AA, "-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study", Eur Heart J, 30, pp.1187~1194 (2009)
- CLSI, "Procedures for the Handling and Processing of Blood Specimen for Common Laboratory Tests; H18-A4", Clinical and Laboratory Standards Institute, ~ (2010)
- Thygesen K, "Third universal definition of myocardial infarction", J Am Coll Cardiol, 60, pp.1581~1598 (2012)
- Ibanez B, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)", Eur Heart J, 39, pp.119~177 (2018)
- Manginas A, "Estimation of coronary flow reserve using the Thrombolysis In Myocardial Infarction (TIMI) frame count method", Am J Cardiol, 83, pp.1562~1565 (1999)
- Myler RK, "Lesion morphology and coronary angioplasty: current experience and analysis", J Am Coll Cardiol, 19, pp.1641~1652 (1992)
- Cutlip DE, "Clinical end points in coronary stent trials: a case for standardized definitions", Circulation, 115, pp.2344~2351 (2007)
- Reichlin T, "Incremental value of copeptin for rapid rule out of acute myocardial infarction", J Am Coll Cardiol, 54, pp.60~68 (2009)
- Slagman A, "Temporal release pattern of copeptin and troponin T in patients with suspected acute coronary syndrome and spontaneous acute myocardial infarction", Clin Chem, 61, pp.1273~1282 (2015)
- von Haehling S, "Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease", Int J Cardiol, 162, pp.27~32 (2012)
- Khan SQ, "C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study", Circulation, 115, pp.2103~2110 (2007)
- Kelly D, "C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction", J Card Fail, 14, pp.739~745 (2008)
- Katan M, "Stress hormones predict cerebrovascular re-events after transient ischemic attacks", Neurology, 76, pp.563~566 (2011)
- Katan M, "Copeptin: a novel, independent prognostic marker in patients with ischemic stroke", Ann Neurol, 66, pp.799~808 (2009)
- Jarai R, "Usefulness of pre-operative copeptin concentrations to predict post-operative outcome after major vascular surgery", Am J Cardiol, 108, pp.1188~1195 (2011)
- Geri G, "Is copeptin level associated with 1-year mortality after out-of-hospital cardiac arrest? Insights from the Paris registry", Crit Care Med, 43, pp.422~429 (2015)
- Ibáñez B, "Evolving therapies for myocardial ischemia", reperfusion injury, 2015, pp.65, 1454~1471
- McMurray JJ, "Clinical practice. Systolic heart failure", N Engl J Med, 362, pp.228~238 (2010)